The experimental study of the effect of raleukin on development of dithizone diabetes in rabbits

Authors

  • I. P. Bukhtiyarova Donetsk National Medical University named after M.Gorky, Ukraine
  • S. M. Drogovoz National University of Pharmacy, Ukraine
  • Eu. M. Kovalenko Donetsk National Medical University named after M.Gorky, Ukraine

DOI:

https://doi.org/10.24959/cphj.14.1268

Keywords:

dithizone diabetes, products of non-enzymatic glycosylation, hypoglycemic action, raleukin

Abstract

In the structure of endocrine diseases diabetes mellitus (DM) occupies the second place after the thyroid gland pathology.
In 2012 there were more than one million people with diabetes in Ukraine, that is why optimization of therapy for this disease is one of the most pressing health and social problems of our time. The pathogenesis basis of the most serious complications of diabetes (thrombosis, atherosclerosis, kidney failure, cataract, etc.) is nonenzymatic glycosylation processes.
Taking into account the presence of antioxidant properties [14] in recombinant receptor antagonist IL-1 raleukin and the hypoglycemic action proven in previous studies it was of interest to study its effect on the initial reactions of nonenzymatic glycosylation. This article presents the results of studying the effect of recombinant receptor antagonist IL-1 raleukin obtained in the State Research Institute of High-Purity Biopharmaceuticals of St. Petersburg on the model of dithizonic diabetes in rabbits. It has been found that on the model of dithizonic diabetes in rabbits recombinant receptor antagonist IL-1 raleukin has a strong hypoglycemic effect, which intensity is not inferior to anakinra and exceeds metformin. The results of these studies indicate the prospects of further study of the anti-diabetic properties of raleukin in order to include this drug in the treatment of type I diabetes.

References

Балаболкин М.И., Клебанова Е.М., Креминская В.М. Лечение сахарного диабета и его осложнений. – М., 2005. – 512 с.

Горбенко Н.І., Полторак В.В., Гладких О.І., Іванова О.В. // Вісник фармації. – 2000. – №1 (21). – С. 44-46.

Дедов И.И. // Вестник Росс. академии мед. наук. – 2012. – №1. – С. 7-13.

Доклінічні дослідження лікарських засобів: Метод. рекоменд. / За ред. чл.-кор. НАМН України О.В.Стефанова. – К.: Авіценна, 2001. – 528 с.

Камышников В.С. Справочник по клиническо-биохимической лабораторной диагностике: в 2-х т. – Мн: Беларусь, 2002. – Т. 1. – 495 с.; Т. 2. – 463 с.

Полторак В.В. // Medicus Amicus. – 2005. – №5. – С. 16.

Сунцов Ю.И., Болотская Л.Л., Маслова О.В. и др. // Сахарный диабет. – 2011. – №1. – С. 15-18.

Тронько М.Д., Чернобровий А.Д. Поширеність цукрового діабету в областях України за 2008 рік / В кн.: Основні показники діяльності ендокринологічної служби України за 2008 рік. – К.: АМНУ, МОЗУ, 2009. – С. 18.

Шумейко О.Г. Експериментальне обґрунтування застосування екстракту з мідії чорноморської (Mytilus galloprovincialis Lam.) у комплексній терапії цукрового діабету : Дис. … канд. мед. наук: 14.01.14 – ендокринологія. – Х., 2009. – 153 с.

Beisswenger P., Ruggiero-Lopez D. // Diabetes Metabol. – 2003. – Vol. 29. №4. – P. 6S95-6S103.

Börjesson A., Carlsson C. // J. Endocrinol. – 2007. – Vol. 192 (2). – P. 381-387.

Cnop M., Welsh N., Jonas J.C. et al. // Diabetes. – 2005. – Vol. 54, Suppl. 2. – P. S97-S107.

Guigas B., Deaille D., Chauvin C. et al. // Biochem J. – 2004. – Vol. 382, №3. – P. 877-884.

Lagathu C., Yvan-Charvet L., Bastard J.P. et al. // Diabetol. – 2006. – №49. – Р. 2162-2173.

Mandrup-Poulsen T., Bendtzen K., Dinarello C.A. et al. // J. Immunol. – 1987. – Vol. 139 (12). – P. 4077-4082.

Sandgerg J.O., Andersson A., Eizirik D.L. et al. // Biochem. Biophys. Res. Commun. – 1994. – Vol. 202 (1). – P. 543-548.

Downloads

Published

2014-03-03

Issue

Vol. 18 No. 1 (2014)

Section

Pre-clinical studies of new drugs

License

Copyright (c) 2014 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).